Company wins generics fight

Posted 17 April 2024 AM

Neurim Pharmaceuticals has won its long-running court case against two generics companies, Apotex and Generic Partners, over patent infringement.

The lawsuit was defending insomnia treatment Circadin, which had the active ingredient of melatonin and was Neurim's first commercial product. It was launched in 2017 when Generic Partners registered Melotin on the ARTG, which contained 2mg of melatonin. There was a counterclaim to try and invalidate the patent.

To see the whole article, please login